Association Between Antibiotic and Outcomes of Chemoimmunotherapy for Extensive‐Stage Small Cell Lung Cancer: A Multicenter Retrospective Study of 132 Patients
ABSTRACT Introduction To evaluate the impact of antibiotic (ATB) exposure on the outcome of chemoimmunotherapy in patients with extensive‐stage small cell lung cancer (ES‐SCLC). Methods In this multicenter retrospective study, 132 patients with ES‐SCLC who received chemoimmunotherapy were included f...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15492 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT Introduction To evaluate the impact of antibiotic (ATB) exposure on the outcome of chemoimmunotherapy in patients with extensive‐stage small cell lung cancer (ES‐SCLC). Methods In this multicenter retrospective study, 132 patients with ES‐SCLC who received chemoimmunotherapy were included from three hospitals in China. Patients receiving ATB within 30 days prior to initiating ICI therapy (p‐ATB) and those receiving concurrent ICI therapy until cessation (c‐ATB)were compared to those who did not (n‐ATB). Progression‐free survival (PFS), overall survival (OS), objective response rate (ORR), and immune‐related adverse events (irAEs) were assessed. To avoid immortal time bias, c‐ATB was analyzed as a time‐dependent covariate in the Cox proportional hazards model. Results Among the 132 patients, 25 were included in the p‐ATB group and 26 in the c‐ATB group, while 81 patients were categorized in the n‐ATB group. Multivariate analysis revealed no significant differences in PFS (aHR = 1.028, 95% CI: 0.666–1.589, p = 0.900) and OS (aHR = 0.957, 95% CI: 0.549–1.668, p = 0.877) between the p‐ATB and n‐ATB groups. Similarly, p‐ATB had no significant impact on ORR (p = 0.510) or irAEs (p = 0.516). The use of c‐ATB had no significant effect on either PFS (aHR: 1.165, 95% CI: 0.907–1.497; p = 0.232) or OS (aHR: 1.221, 95% CI: 0.918–1.624; p = 0.171) by multivariate analysis. Conclusions p‐ATB has no significant impact on PFS, OS, ORR, or the incidence of irAEs in ES‐SCLC patients receiving chemoimmunotherapy. Similarly, c‐ATB does not seem to affect PFS or OS. |
|---|---|
| ISSN: | 1759-7706 1759-7714 |